 Questions about deferaprone's use at Toronto's University Health Network still make headlines. Olivieri faced down the threats and lawsuits, and in Arthur's words, became an international icon for standing up to big pharma. But the ethical questions about corporate funding of research remain. Is that a lost battle at this stage?